Viatris Plots ‘Significant’ Restructuring As Mylan-Upjohn Merger Completes
New Company Aims To Achieve $1bn Of Synergies Through Restructuring
Nearly 16 months after it was first announced, the $12bn merger of Mylan and Pfizer’s Upjohn has completed, with the resulting company Viatris preparing to unveil restructuring plans by the end of 2020.
You may also be interested in...
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Presenting its last ever financial earnings as a standalone company, Mylan revealed plans to host an Investor Day in the first quarter of next year to discuss the strategic direction of Viatris, Mylan’s proposed combination with Pfizer’s Upjohn which is due to close later this month.